Condition
Acute Lymphoblastic Leukemia Recurrent
Total Trials
5
Recruiting
1
Active
2
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
Early P 1 (1)
P 1 (3)
Trial Status
Terminated2
Completed1
Active Not Recruiting1
Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03853616Phase 1Active Not RecruitingPrimary
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
NCT07371403Not ApplicableRecruiting
MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NCT04049383Phase 1Terminated
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
NCT03957915Early Phase 1CompletedPrimary
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
NCT03705507Phase 1Terminated
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
Showing all 5 trials